全文获取类型
收费全文 | 133943篇 |
免费 | 10625篇 |
国内免费 | 7591篇 |
专业分类
耳鼻咽喉 | 975篇 |
儿科学 | 5047篇 |
妇产科学 | 3995篇 |
基础医学 | 20700篇 |
口腔科学 | 3251篇 |
临床医学 | 10491篇 |
内科学 | 19078篇 |
皮肤病学 | 1990篇 |
神经病学 | 9398篇 |
特种医学 | 2694篇 |
外国民族医学 | 59篇 |
外科学 | 10780篇 |
综合类 | 24109篇 |
现状与发展 | 36篇 |
一般理论 | 1篇 |
预防医学 | 6876篇 |
眼科学 | 3419篇 |
药学 | 10795篇 |
30篇 | |
中国医学 | 3819篇 |
肿瘤学 | 14616篇 |
出版年
2024年 | 210篇 |
2023年 | 1245篇 |
2022年 | 2635篇 |
2021年 | 3955篇 |
2020年 | 3433篇 |
2019年 | 3316篇 |
2018年 | 3289篇 |
2017年 | 3823篇 |
2016年 | 4143篇 |
2015年 | 4363篇 |
2014年 | 7069篇 |
2013年 | 9095篇 |
2012年 | 7306篇 |
2011年 | 8821篇 |
2010年 | 7401篇 |
2009年 | 7274篇 |
2008年 | 7721篇 |
2007年 | 8222篇 |
2006年 | 7712篇 |
2005年 | 7090篇 |
2004年 | 6143篇 |
2003年 | 5407篇 |
2002年 | 4618篇 |
2001年 | 4102篇 |
2000年 | 3532篇 |
1999年 | 2896篇 |
1998年 | 2506篇 |
1997年 | 2166篇 |
1996年 | 1818篇 |
1995年 | 1537篇 |
1994年 | 1317篇 |
1993年 | 1038篇 |
1992年 | 925篇 |
1991年 | 772篇 |
1990年 | 732篇 |
1989年 | 550篇 |
1988年 | 426篇 |
1987年 | 375篇 |
1986年 | 362篇 |
1985年 | 514篇 |
1984年 | 415篇 |
1983年 | 269篇 |
1982年 | 357篇 |
1981年 | 263篇 |
1980年 | 212篇 |
1979年 | 172篇 |
1978年 | 150篇 |
1977年 | 119篇 |
1976年 | 102篇 |
1975年 | 66篇 |
排序方式: 共有10000条查询结果,搜索用时 194 毫秒
41.
《药学学报(英文版)》2020,10(7):1294-1308
A great challenge in multi-targeting drug discovery is to identify drug-like lead compounds with therapeutic advantages over single target inhibitors and drug combinations. Inspired by our previous efforts in designing antitumor evodiamine derivatives, herein selective histone deacetylase 1 (HDAC1) and topoisomerase 2 (TOP2) dual inhibitors were successfully identified, which showed potent in vitro and in vivo antitumor potency. Particularly, compound 30a was orally active and possessed excellent in vivo antitumor activity in the HCT116 xenograft model (TGI = 75.2%, 150 mg/kg, p.o.) without significant toxicity, which was more potent than HDAC inhibitor vorinostat, TOP inhibitor evodiamine and their combination. Taken together, this study highlights the therapeutic advantages of evodiamine-based HDAC1/TOP2 dual inhibitors and provides valuable leads for the development of novel multi-targeting antitumor agents. 相似文献
42.
Javed A. Shaik Nima Estharabadi Ronda S. Farah Maria K. Hordinsky 《Experimental dermatology》2020,29(10):1004-1011
Platelet α-granules release growth factors (GFs) that promote healing and tissue regeneration. Platelet-rich plasma (PRP) is shown to be beneficial in treating alopecia, and however, clinical response can be inconsistent. Due to several fold enrichment of platelets secreting large quantities of GFs following PRP injections, heterogeneity in amounts of GFs secreted by platelets may contribute to inconsistent clinical responses. Herein, we evaluated factors that could potentially contribute to heterogeneous secretion of GFs by platelets. We measured platelet secretion of transforming growth factor beta1 (TGFβ1), platelet-derived growth factor (PDGF-BB), epidermal growth factor (EGF), vascular endothelial growth factor (VEGF) and fibroblast growth factor (FGF2) in aliquots of de-identified PRP samples from female patients undergoing therapy in the hair disease clinic. Although secretion of GFs by platelets was comparable in PRP samples of patients with non-cicatricial and cicatricial alopecia, a Shapiro-Wilk test for normal distribution indicated significant variability across all patient samples. The amount of GF secreted by platelets was comparable when PRP prepared from two FDA-cleared devices with distinct techniques were compared. We provide evidence of platelets secreting heterogeneous amounts of GFs within each sample as high and low secretion of random factors could be simultaneously detected. These results suggest inherent heterogeneity in secretion of GFs by platelets in patient samples that are not influenced by the device used to prepare PRP. Since some GFs could have antagonistic effects on hair growth, a balance between amounts of growth promoting and inhibiting factors may be crucial in determining clinical response to PRP therapy. 相似文献
43.
44.
45.
- Download : Download high-res image (66KB)
- Download : Download full-size image
46.
47.
《Molecular therapy》2020,28(6):1432-1441
- Download : Download high-res image (155KB)
- Download : Download full-size image
48.
49.
Roberto V.P. Ribeiro Mitesh V. Badiwala Danny Ramzy Laura C. Tumiati Vivek Rao 《The Journal of thoracic and cardiovascular surgery》2019,157(2):615-625.e1
Objective
Hypertonic saline (HTS) has potent immune and vascular effects. We assessed recipient pretreatment with HTS on allograft function in a porcine model of heart transplantation and hypothesized that HTS infusion would limit endothelial and left ventricular (LV) dysfunction following transplantation.Methods
Heart transplants were performed after 6 hours of cold ischemic storage. Recipient pigs were randomized to treatment with or without HTS (7.5% NaCl) before cardiopulmonary bypass (CPB). Using a myograft apparatus, coronary artery endothelial-dependent (Edep) and -independent (Eind) relaxation was assessed. LV performance was determined using pressure-volume loop analysis. Pulmonary interleukin (IL)-2, IL-6, and tumor necrosis factor (TNF)-α expression was measured.Results
Weaning from CPB and LV performance after transplantation were improved in HTS-treated animals. Successful weaning from CPB was greater in the HTS-treated hearts (8 of 8 vs 2 of 8; P < .05). Mean LV functional recovery was improved in the HTS-treated animals, as assessed by preload recruitable stroke work (65 ± 10% vs 27 ± 10%; P < .001) and end-systolic elastance (55 ± 7% vs 37 ± 4%; P < .001). Treatment with HTS resulted in improved Edep (mean maximum elastance [Emax], 56 ± 5% vs 37 ± 7%; P < .001) and Eind (mean Emax%, 77 ± 6% vs 52 ± 4%; P < .001) vasorelaxation compared with control. Pulmonary expression of IL-2, IL-6, and TNF-α increased following transplantation, whereas HTS therapy attenuated IL production (P < .001). Transplantation increased plasma TNF-α levels and LV TNF-α expression, whereas HTS prevented this up-regulation (P < .001).Conclusions
Recipient HTS pretreatment preserves allograft vasomotor and LV function, and HTS therapy limits CPB-induced injury. HTS may be a novel recipient intervention to prevent graft dysfunction. 相似文献50.
Lesley A. Inker Morgan E. Grams Andrew S. Levey Josef Coresh Massimo Cirillo John F. Collins Ron T. Gansevoort Orlando M. Gutierrez Takayuki Hamano Gunnar H. Heine Shizukiyo Ishikawa Sun Ha Jee Florian Kronenberg Martin J. Landray Katsuyuki Miura Girish N. Nadkarni Carmen A. Peralta Dietrich Rothenbacher Mark Woodward 《American journal of kidney diseases》2019,73(2):206-217